Analysis of curative efficacy of transjugular intrahepatic portosystemic shunt using viabahn stent in the treatment of Budd-Chiari syndrome with extensive hepatic vein occlusion
10.3760/cma.j.cn501113-20200331-00151
- VernacularTitle:采用Viabahn支架行经颈静脉肝内门体分流术治疗肝静脉广泛闭塞布加综合征的疗效分析
- Author:
Chen ZHAO
1
;
Qingqiao ZHANG
;
Hao XU
;
Ning WEI
;
Yanfeng CUI
;
Hongtao LIU
;
Wenliang WANG
;
Jinchang XIAO
;
Maoheng ZU
Author Information
1. 徐州医科大学附属医院介入放射科 221006
- Keywords:
Budd-Chiari syndrome;
Transjugular intrahepatic portosystemic shunt;
Viabahn stent
- From:
Chinese Journal of Hepatology
2021;29(10):972-976
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of transjugular intrahepatic portosystemic shunt (TIPS) using viabahn stent in patients with Budd-Chiari syndrome (BCS) with extensive hepatic vein occlusion.Methods:Technical success rates, portal pressure gradient (PPG), complications and shunt patency rate of 25 cases with BCS with extensive hepatic vein occlusion treated by TIPS using viabahn stent were retrospectively analyzed. Color Doppler ultrasound was used for postoperative follow-up. Patency rates were evaluated by Kaplan-Meier curve.Results:The technical success rate of TIPS was 100%. Mean PPG decreased from (22.7 ± 6.2) mmHg preoperatively to (9.7 ± 2.6) mmHg postoperatively ( t = 9.58, P < 0.05). Hepatic encephalopathy incidence was 8.0% (2/25), and there were no complications such as intra-abdominal hemorrhage. Twenty-five cases were followed up for 1 to 39 ( mean 19.0 ± 11.9) months, and one patient died of liver failure three months after interventional treatment. The primary patency rates at 1, 2, and 3 years after interventional treatment were 91.3%, 91.3%, and 78.2%, respectively, while the repatency rates were 100%, 92.9%, and 92.9%, respectively. Conclusion:TIPS using viabahn stent can bring better short-term and mid-term curative efficacy in treatment of BCS with extensive hepatic vein occlusion.
